PatientsVille.com LogoPatientsVille.com

Hyperalgesia | Effect of Gabapentin on Pain of the Second Cataract Surgery

Hyperalgesia research study

What is the primary objective of this study?

Gabapentin pretreatment may reduce hyperalgesia occurring at the second surgery in serial, bilateral cataract surgery.

Who is eligible to participate?

Inclusion Criteria: - Patient of ASA(American Cociety of Anesthesiology) class I, II, III between age 20 to 80, scheduled for serial bilateral cataract surgery(1 weel interval) Exclusion Criteria: - refuse to participate - BMI<16 or BMI >30 - severe cardiovascular, pulmonary, renal disease - alcohol or drug abuse - currently taking CNS(central nervous system) inhibitory drugs - taking antiacids - depressive disorder pregnancy

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Hyperalgesia

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:gabapentin100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery

Drug:placebothe same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Gabapentingabapentin pretreatment

Placeboplacebo drug pretreatment

Study Status

Unknown status

Start Date: July 2014

Completed Date: February 2016

Phase: Phase 4

Type: Interventional

Design:

Primary Outcome: proportion of subjects who answer that "pain was greater" in the second eye surgery

Secondary Outcome: perioperative pain

Study sponsors, principal investigator, and references

Principal Investigator:

Lead Sponsor: Seoul National University Hospital

Collaborator:

More information:https://clinicaltrials.gov/show/NCT02127853

Discuss Gabapentin